NeurologyLive® Mind Moments® Podcast Por NeurologyLive arte de portada

NeurologyLive® Mind Moments®

NeurologyLive® Mind Moments®

De: NeurologyLive
Escúchala gratis

Acerca de esta escucha

 Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more.

For more expert insight into neurology, visit NeurologyLive.com. Ciencia Enfermedades Físicas Hygiene & Healthy Living
Episodios
  • 144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead

    144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead
    Jun 27 2025
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

    In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joseph Sullivan, MD, director of the Pediatric Epilepsy Center at UCSF, joins Mind Moments to discuss the clinical distinctions between Dravet syndrome and Lennox-Gastaut syndrome (LGS). Sullivan outlines the unique diagnostic profiles, seizure presentations, and genetic underpinnings of each disorder, while also addressing how genetic testing has transformed the approach to Dravet syndrome in particular. He speaks on the future of targeted therapies, highlighting ongoing research in disease-modifying treatments and n-of-1 trials, especially for ultra-rare epilepsies. Additionally, Sullivan explores how the clinical trial landscape is evolving—emphasizing the need for biomarkers, innovative trial design, and better tools for seizure monitoring to improve outcomes in these complex pediatric epilepsies.

    Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

    Episode Breakdown:
    • 1:00 – Key differences in phenotype and diagnosis between Dravet syndrome and LGS
    • 3:00– The evolution of genetic testing and how it’s improved Dravet diagnosis and outcomes
    • 5:25 – Opportunities and limitations in scaling genetic testing more broadly
    • 6:35 – Neurology News Minute
    • 8:45 – Research pipelines: disease-modifying therapies, n-of-1 trials, and future directions
    • 10:20 – Innovations in clinical trial design and the need for better seizure monitoring and biomarkers

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP
    • FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis
    • Grace Therapeutics Submits NDA for GTX-104 to Treat Aneurysmal Subarachnoid Hemorrhage

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    18 m
  • 143: Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease

    143: Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease
    Jun 13 2025
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

    In this episode, "Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease" Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center, discusses the phase 3 exPDite-2 trial evaluating bemdaneprocel, an investigational cell therapy for Parkinson disease (PD). Pahwa explains the rationale behind cell replacement therapy as a means to restore dopamine production, outlining the progression from fetal tissue implants to stem cell–derived dopaminergic neurons. He details key elements of the study design, including patient selection criteria, trial endpoints, and long-term goals. Reflecting on decades of research in this space, he emphasizes the potential impact of a one-time, hardware-free surgical option and how this novel approach could complement or shift the current treatment landscape. While many questions remain, Pahwa highlights the promise of bemdaneprocel as a next-generation option in Parkinson care.

    Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

    Episode Breakdown:
    • 1:00 – Mechanism and rationale behind bemdaneprocel as a dopaminergic cell therapy
    • 3:00– Key design considerations for conducting a registrational phase 3 cell therapy trial
    • 5:25 – Trial structure, eligibility criteria, and ongoing patient recruitment
    • 6:35 – Neurology News Minute
    • 8:45 – Significance of reaching phase 3 with a cell therapy in Parkinson disease
    • 10:20 – Future role of cell therapy within the Parkinson disease treatment landscape
    • 12:10 – Unique aspects of the exPDite-2 trial and what sets it apart from earlier efforts

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • BTK Inhibitor Fenebrutinib Demonstrates Long-Term Suppression of MS Activity in Open-Label Extension
    • REGENXBIO Reports Positive Phase 1/2 Data for Higher Dose of RGX-202 in Duchenne Muscular Dystrophy
    • NewAmsterdam Pharma Reports Positive Topline Data of Alzheimer Agent Obicetrapib from Phase 3 BROADWAY Trial

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    15 m
  • 142: World MS Day: Raising Awareness, Evolving Care, and Empowering Patients

    142: World MS Day: Raising Awareness, Evolving Care, and Empowering Patients
    May 30 2025
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

    In this episode, "World MS Day: Raising Awareness, Evolving Care, and Empowering Patients," Taylor Hess, MD, a multiple sclerosis specialist at the Michigan Institute for Neurological Disorders (MIND), shares insights in recognition of World MS Day. She reflects on the importance of raising global awareness for MS, the need for equitable care, and the evolving focus of research and treatment. Dr. Hess discusses underrecognized symptoms like fatigue and cognitive dysfunction, and emphasizes the value of the upcoming diagnostic criteria update in enabling earlier intervention. She highlights key research priorities—including progressive MS, symptom management, and remyelination—and speaks to the importance of holistic, lifestyle-informed care. Finally, she shares advice for clinicians on how to communicate a new MS diagnosis with empathy, clarity, and empowerment.

    Looking for more multiple sclerosis discussion? Check out the NeurologyLive® Multiple sclerosis clinical focus page.

    Episode Breakdown:
    • 1:00 – Significance of World MS Day and the importance of global MS awareness
    • 2:05– Commonly recognized vs overlooked MS symptoms in patient care
    • 3:10 – Transitioning to updated MS diagnostic criteria and the need for global provider education
    • 4:15 – Neurology News Minute
    • 6:30 – Research priorities: progressive MS, symptom management, and remyelination strategies
    • 7:35 – The role of lifestyle, risk factor control, and holistic care in MS management
    • 8:50 – Communicating MS diagnosis with empathy, support, and resource guidance

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • FDA Approves First Autoinjector Form of DHE for Acute Migraine and Cluster Headache
    • FDA Clears Lumipulse Plasma Ratio as First Blood Test for Diagnosing Alzheimer Disease
    • Once-Daily Oral Pill for Obstructive Sleep Apnea Shows Promising Phase 3 Results, Paving Way for FDA Submission

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    12 m
Todavía no hay opiniones